Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Analysis of 34 candidate genes in bupropion and placebo remission.

The international journal of neuropsychopharmacology - 1 May 2013

Tiwari Arun K, Zai Clement C, Sajeev Gautam, Arenovich Tamara, Müller Daniel J, Kennedy James L

Abstract excerpt

There is considerable variability in the rate of response and remission following treatment with antidepressant drugs or placebo in depression patients. No pharmacogenetic studies of bupropion response have been done. We investigated 532 tagging single nucleotide polymorphisms (SNPs) in 34 candidate genes for association with remission and response to either bupropion (n=319) or placebo (n=257) in patients with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genetic Association Studies
Share to Antidepressive Agents, Second-Generation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bupropion

Share to Depressive Disorder, Major

Share to Double-Blind Method

Share to Receptor, Serotonin, 5-HT2A

Share to Remission Induction

Share to Treatment Outcome

Source

Identifiers

PMID: 22947179
DOI: 10.1017/S1461145712000843

Genes

MAOA
HTT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Analysis of 34 candidate genes in bupropion and placebo remission.PMID 22947179Read ↗

Analysis of 23andMe antidepressant efficacy survey data: implication of circadian rhythm and neuroplasticity in bupropion responseSemantic proximity Read ↗

Smoking Cessation Pharmacogenetics: Analysis of Varenicline and Bupropion in Placebo-Controlled Clinical TrialsSemantic proximity Read ↗

Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessationSemantic proximity Read ↗

A genomewide association study of citalopram response in major depressive disorder.Semantic proximity Read ↗

Dopamine D4 receptor gene variation moderates the efficacy of bupropion for smoking cessation.Semantic proximity Read ↗

Genetic variants in the serotonin transporter influence the efficacy of bupropion and nortriptyline in smoking cessation.Semantic proximity Read ↗

No evidence for a major role of polymorphisms during bupropion treatment.Semantic proximity Read ↗

The association of COMT genotype with buproprion treatment response in the treatment of major depressive disorder.Semantic proximity Read ↗

Genomic predictors of remission to antidepressant treatment in geriatric depression using genome-wide expression analyses: a pilot study.Semantic proximity Read ↗

Nicotinic acetylcholine receptor beta2 subunit gene implicated in a systems-based candidate gene study of smoking cessation.Semantic proximity Read ↗

Effect of genetic polymorphisms on smoking cessation: a trial of bupropion in Korean male smokers.Semantic proximity Read ↗

Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.